Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from SNDL Inc

Pharma Buy, Hold, or Sell: 4 Stocks Worth Considering

The pharmaceutical industry is anticipated to thrive as demand grows and technology advances. However, given the macroeconomic uncertainties, let us analyze leading pharma stocks Zoetis (ZTS), Verano Holding (VRNOF), Canopy Growth (CGC) and SNDL (SNDL) to identify whether they are a Buy, Hold, or Sell. Read on.

StockNews.com

SNDL Inc. (SNDL) vs. GSK plc (GSK): Analyzing the Better Long-Term Pharma Investment

Amid the burgeoning technological innovation and its seamless integration, investors' interest seems to gravitate toward the pharmaceutical industry. Keeping this in mind, which of the stocks, SNDL Inc. (SNDL) and GSK plc (GSK), could be a better long-term investment? Let's find out.

StockNews.com

What Lies Ahead for SNDL Inc. (SNDL) and Canopy Growth (CGC)?

The cannabis industry is undergoing a turbulent time due to legalization troubles and its struggles to realize gains. Amid this, would it be wise to invest in SNDL Inc. (SNDL) and Canopy Growth (CGC) now? Keep reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Which of These 3 Pharma Stocks Are a Buy?

The pharma industry is expected to experience substantial growth in the coming years with expanding global medical needs. So, which of these pharma stocks, Ipsen (IPSEY), Collegium Pharmaceutical (COLL), and SNDL (SNDL), are a buy now? Keep reading.

StockNews.com

Is It Finally Time to Buy Shares of SNDL Inc. (SNDL)?

Despite aggressive expansionary strategies, Canadian cannabis producer SNDL Inc. (SNDL) exhibits weak profitability. Therefore, should investors buy the stock now? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

2 Must-Have Pharma Stocks to Buy in August, 1 to Sell

The pharmaceutical industry is poised to thrive amid increasing global healthcare demand. Hence, two quality pharma stocks, Johnson & Johnson (JNJ) and Novartis AG (NVS), could be solid portfolio additions. However, avoiding fundamentally weak stock SNDL Inc. (SNDL) could be a wise choice. Read more.

StockNews.com

Buy, Hold or Sell in July: Canopy Growth (CGC) and SNDL Inc. (SNDL)

Although the cannabis industry shows long-term growth potential, its near-term performance is hampered by intense regulations and limited financing. So, let's analyze whether you should Buy, Hold or Sell cannabis stocks SNDL (SNDL) and Canopy Growth (CGC).

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Is SNDL Inc. (SNDL) a Buy or Sell this Summer?

Canadian cannabis producer SNDL (SNDL) witnessed solid revenue growth over the past few years. However, its bottom line is in the red. Also, considering the heightened regulatory pressures, is the stock worth buying now? Keep reading.

StockNews.com

Which Pharma Stock is a Pick for June: Pfizer (PFE) or SNDL Inc. (SNDL)?

The pharmaceutical industry is known for its resilience during challenging economic times, primarily due to the inelastic demand for essential medicines. As the specter of a potential recession hangs over the market, let us analyze two leading players in the sector, Pfizer (PFE) and SNDL (SNDL), to find the better…

StockNews.com

Is SNDL Inc. (SNDL) Overbought?

Canadian cannabis company SNDL Inc. (SNDL) enjoys major investor attention and belongs to the Robinhood top 100 stocks list. However, should investors consider buying this stock now? Read more….

StockNews.com

Johnson & Johnson (JNJ) and SNDL Inc. (SNDL) -- Buy or Sell?

Investing in healthcare stocks could help hedge against economic downturns. Thus, Johnson & Johnson (JNJ) could be worth buying. However, I think SNDL (SNDL) is best avoided considering its weak fundamentals. Read on.

StockNews.com

2 Cannabis Stocks to Think Twice About Before Buying

The cannabis industry has been facing several economic and regulatory challenges. Demand has also slowed amid a glut in supply. With the Fed unlikely to stop interest rate hikes, the economy could enter a recession this year. Amid this backdrop, it could be wise to avoid fundamentally weak cannabis stocks…

StockNews.com

3 Stocks You Should Sell Now

After the blow of several bank failures in recent weeks, investors are now eyeing the Fed’s policy decision, scheduled to release today. Given fears of an economic downturn, eliminating fundamentally weak stocks Lucid Group (LCID), Robinhood Markets (HOOD), and SNDL Inc. (SNDL) from your watchlist could be wise before the…

StockNews.com

3 Stocks to Remove From Your Watchlist

The recent bank failures have stoked fears of financial instability, and the Fed is widely expected to opt for a small or no rate hike this week. With fears of an economic downturn on the horizon, it could be wise for investors to remove fundamentally weak stocks Plug Power (PLUG),…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

If You Own This Drug Manufacturer Stock, It’s Time to Sell

Canadian cannabis producer SNDL (SNDL) has made several acquisitions to support its growth. Although the company witnessed solid revenue growth in its last reported quarter, its bottom line was in the red. The company’s return to profitability remains uncertain. Moreover, given the regulatory challenges, I think this fundamentally weak stock…

StockNews.com

2 Risky Cannabis Stocks to Avoid Right Now

Following remarkable growth in recent years, the cannabis industry faced various legal and economic challenges, including overproduction amid high inflation, high taxes, and increased material costs impacting overall sales in 2022. The industry will likely remain under pressure amid concerns over rising inflation and a potential recession. Hence, it could…

StockNews.com

2 Pharma Stocks to Buy Right Now and 1 You Might Want to Consider Selling

The pharmaceutical industry is evolving with personalized medicines and the rapid adoption of RPM technology, which should boost growth. Moreover, with a recession lurking, fundamentally strong pharma stocks AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) might be ideal buys. However, SNDL (SNDL) might be best avoided. Keep reading to know why.

StockNews.com

1 Medical Stock to Buy in February and 1 to Avoid Like the Plague

The medical industry is expected to grow due to increasing healthcare requirements and federal support. Moreover, given the inelastic demand for healthcare products and services, fundamentally strong medical stock Nature's Sunshine Products (NATR) could be an ideal buy this month. However, SNDL (SNDL) might be best avoided, considering its weak…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Medical Stocks with Excellent Vital Signs and 1 to Avoid

Amid strong demand for medical products, technological advancements, and government support, the healthcare industry’s growth prospect looks promising in the near future. Therefore, quality medical stocks UnitedHealth Group (UNH), Abbott Laboratories (ABT), and Nature’s Sunshine Products (NATR) might be solid buys now. However, fundamentally weak SNDL Inc. (SNDL) might be…

Benzinga

Why Is SNDL Trading Higher Today?

SNDL Inc. (NASDAQ: SNDL) shares are trading 8.85% higher at $2.83 per share during Monday’s pre-market session.

Benzinga

SNDL To Buy Superette Assets Including 6 Retail Stores, Enters Into A Bid Agreement

SNDL Inc. (NASDAQ: SNDL) has entered into an agreement of purchase and sale with Superette Inc., pursuant to which it proposes to acquire substantially all of the business and assets of Superette through a hybrid asset purchase and 'reverse vesting' transaction.

Benzinga

SNDL To Buy Valens For $105M In Stock Creating Cannabis Behemoth

SNDL Inc. (NASDAQ: SNDL) and The Valens Company Inc.

Benzinga

Reddit's Favorite Weed Stock SNDL Posts Staggering Revenue Growth, But Cantor Lowers Price Target

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

Lucid Group

121 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.